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Purpose: We aim to evaluate the accuracy and effectiveness of an automatically converted radia-
tion therapy plan between Radixact machines by comparing the original plan with the transferred 
plan.
Methods: The study involved a total of 20 patients for each randomly selected treatment site who 
received radiation treatment with Radixact. We set up the cheese phantom (Gammex RMI, 
Middleton, WI, USA) with an Exradin A1SL ion chamber (Standard Imaging, Madison, WI, USA) and 
GAFCHROMIC EBT3 film (International Specialty Products, Wayne, NJ, USA) inserted. We used 
three methods to evaluate an automatically converted radiation therapy plan using the features of 
the Plan transfer. First, we evaluated and compared Planning target volume (PTV) coverage (homo-
geneity index, HI; conformity index, CI) and organs at risk (OAR) dose statistics. Second, we com-
pared the absolute dose using an ion chamber. Lastly, we analyzed gamma passing rates using 
film.
Results: Our results showed that the difference in PTV coverage was 1.72% in HI and 0.17% in CI, 
and majority of the difference in OAR was within 1% across all sites. The difference (%) in absolute 
dose values was averaging 0.74%. In addition, the gamma passing rate was 99.64% for 3%/3 mm 
and 97.08% for 2%/2 mm.
Conclusions: The Plan transfer function can be reliably used in appropriate situations.
Keywords: Plan transfer, Radixact, Intensity modulated radiation therapy, Integrated Data Management 
System, Gamma passing rate
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Introduction
The continuity of treatment in radiation therapy is very 
important. However, unintended treatment interruptions 
may occur, and each hospital should establish and pre-
pare protocols for these situations. In this situation, the 
only way to continue treatment is to repair the machine if 
there is only one treatment machine in the hospital, but 
if there are more than two treatment machines with the 
same function in the hospital, continuous treatment can 
be considered if the treatment plan can be converted to 
a machine that works properly. Tomotherapy (Accuray, 
Sunnyvale, CA, USA) was developed at the University of 
Wisconsin [1,2], and in 2018, the first Radixact system (Ac-
curay) in Korea was released for clinical use. Radixact oper-
ates using a data management system called the Integrated 
Data Management System (IDMS). In addition, one of the 
sub-features of IDMS is a Plan transfer function. This fea-
ture allows clinicians to transfer a plan from a previously 
planned machine to another machine registered in IDMS 
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in unavoidable or emergency situations. Samsung Medical 
Center (Seoul, Korea) evaluated this Plan transfer function 
between TOMO HDA (Accuray) and Radixact by comparing 
the dose required by the normal organ and the target or-
gan [3]. Furthermore, there were also attempts to continue 
treatment by using third-party treatment planning systems 
(TPS). RayStation’s fallback (FB) planning was shifted from 
a helical tomotherapy (HT) plan to a Linac plan, where FB 
changes in each reference plan were converted to plans 
that can be delivered on a different machine [4,5]. What 
both the FB and the Plan transfer function have in common 
is the ability to convert treatment plans. However, the plan 
transfer can be converted only to tomotherapy connected 
by IDMS, but FB can be converted regardless of whether the 
linear accelerators are L-shape or O-shape. In this study, we 
will cover the Plan transfer function that can be used with-
out a TPS. St. Vincent’s Hospital (Suwon, Korea) installed 
two Radixact machines in July 2018, which we will refer to 
as machines A and B. We have been able to continue the 
treatment of patients using an automatically converted ra-
diation therapy plan in the event of machine breakdown or 
other unexpected contingencies. When transferring a treat-
ment plan from one machine to another, we verified IMRT 
quality assurance (QA) using an electronic portal imaging 
device and a Dose Volume Histogram (DVH). However, 
these QAs were not sufficient to assess the accuracy of the 
transferred plan. For a more definite verification, we made a 
QA plan using a phantom that utilized an ion chamber and 
film to measure the dose and confirm the two-dimensional 
dose distribution [6.7]. The purpose of this study is to evalu-
ate the dosimetric consistency of the plan transfer features 
by installing the same measuring equipment on the original 
plan machine and the transferred plan machine.
Materials and Methods
1. Patient characteristics and planning
In this study, 20 patients treated with Radixact at St. 
Vincent’s Hospital were selected randomly and received 
Institutional Review Board (IRB) of the Catholic Medical 
Center, the Catholic University of Korea approval (proto-
col no. VC19RASI0237). The study examined four patient 
cases for each of the following treatment sites: brain, head 
and neck (H&N), chest, abdomen, and pelvis. As much as 
possible, we tried to select patients with various diseases 
at each treatment site. Treatment plan conversion was ac-
complished using Accuray Precision (Accuray, Sunnyvale, 
CA, USA) version 1.1.1.1. The plan transfer feature was used 
to convert each patient’s plan from the original machine to 
another machine. To check the characteristics of the ma-
chine sequence, 10 cases were converted from machine A 
to B, and the remaining 10 cases were converted from ma-
chine B to A. Then, we made a QA plan wherein a phantom 
with an ion chamber and film inserted was used, as shown 
in Fig. 1. By doing so, we were able to obtain absolute dose 
and coronal plane dose distributions.
2. Set up and delivery
We measured the daily output of the machine reflecting 
the temperature and pressure of each treatment room to 
eliminate condition deviations on the measurements. We 
set up the cheese phantom (Gammex RMI, Middleton, WI, 
USA) with a certified Exradin A1SL ion chamber (Standard 
Imaging, Madison, WI, USA) and GAFCHROMIC EBT3 film 
(International Specialty Products, Wayne, NJ, USA) inserted. 
In addition, we measured QA on the original plan machine 
and on the transferred plan machine simultaneously. To 
verify the effectiveness of the Plan transfer function, the 
following methods were used: (1) comparison of PTV cov-






Fig. 1. Quality assurance plan setup image with cheese phantom, 
film, and ion chamber.
Progress in Medical Physics   Vol. 31, No. 4, December 2020 155
www.ksmp.or.kr
dose using the ion chamber, and (3) gamma passing rates 
analysis using the film [8-11].
1) Plan quality comparison
The DVH was verified in both the original transferred 
plans. Target coverage was compared with the conformity 
index (CI) and the homogeneity index (HI). CI was defined 
by the following equation [12],
CI=PIV/TV  (1)
where TV is the target volume and PIV is the target volume 
covered by the prescription isodose volume. HI was the 
uniformity of dose distribution in the target volume and 
was defined as below [13],
HI=(D2%–D98%)/Dprescription*100%  (2)
where D2% and D98% are doses of 2% and 98% of the target 
volume, respectively. For OAR comparison, the maximum 
dose and mean dose of normal organs near the target were 
compared.
a b
Fig. 2. The measured film image of (a) 




Fig. 3. Analysis image of gamma criteria (a) 3%/3 mm and (b) 2%/2 mm for prostate patients in RIT 113 (Radiological Imaging Technology, 
Colorado Springs, CO, USA) between the original plan and the transferred plan.
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2) Ion chamber measurement
To compare absolute doses, we installed the same certi-
fied ion chambers in both the original and the transferred 
treatment plan machines. We measured the absolute do-
simetry with static output and found that the average differ-
ence between the static output and the rotational output is 
0.2%. The measured values reflected the daily output at the 
time of measurement.
3) Film measurement.
Fig. 2 shows measured film images of the original plan 
and the transferred plan. The IMRT QA difference between 
the original plans and the transferred plans was analyzed 
by applying gamma indexes of 3%/3 mm and 2%/2 mm 
relative tolerance with automatic registration using RIT 113 
(Radiological Imaging Technology, Colorado Springs, CO, 
USA), as shown in Fig. 3 [14]. Comparison of dosimetric 
data between the original plans and the transferred plans 
was performed using the Wilcoxon matched pair signed-
rank test to clarify the differences in results. A value of 
P≤0.05 was considered a significant value [15].
Results
1. DVH comparison
1) PTV dose coverage
The PTV coverage showed similar results at almost all 
treatment sites between the original plans and the trans-
ferred plans, as shown in Table 1, 2. The CI showed a maxi-
mum difference of 1.00% in the pelvis and a difference 
within 0.32% in other sites. The overall average of the CI 
difference (%) was 0.18%, and the P-value between the two 
groups was 0.23, indicating an insignificant CI difference 
(%). The HI showed a difference of up to 8.72% and 7.77% 
in the H&N site and the chest site, respectively, but it was 
within 2.82% in the remaining three cases. In addition, the 
P-value between the groups was 0.35; hence, there was 
Table 1. Planning target volume coverage comparisons of the 








Brain 1 A 0.13 1.00
B
2 A 0.31 2.30
B
Head and  
neck
5 A 0.15 0.79
B
6 A 0.13 0.78
B
Chest 9 A 0.02 0.46
B
10 A 0.17 7.77
B
Abdomen 13 A 0.04 1.06
B
14 A 0.16 2.82
B
Pelvis 17 A 0.20 0.63
B
18 A 0.09 1.74
B
Average 0.14 1.94
Standard deviation 0.08 2.19
CI, Conformity Index; HI, Homogeneity Index.
The CI and HI difference (%) values are shown, respectively.
Table 2. Planning target volume coverage comparisons of the 








Brain 3 B 0.32 0.00
A




7 B 0.11 0.80
A
8 B 0.16 8.72
A
Chest 11 B 0.06 1.05
A
12 B 0.05 0.00
A
Abdomen 15 B 0.17 1.29
A
16 B 0.09 0.55
A
Pelvis 19 B 0.13 0.18
A
20 B 1.00 0.87
A
Average 0.21 1.50
Standard deviation 0.28 2.59
CI, Conformity Index; HI, Homogeneity Index.
The CI and HI difference (%) values are shown, respectively.
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Table 3. Organs at risk dose differences (%) between the original plans and the transferred plans
Brain 1 2 3 4
R lens (Dmax) −1.89 1.59 1.43 4.34
L lens (Dmax) 0.00 2.33 −0.17 0.00
R eye (Dmax) −0.47 0.14 0.59 −0.30
L eye (Dmax) −0.19 −0.64 0.60 0.45
R optic nerve (Dmax) −0.27 −0.20 0.55 0.24
L optic nerve (Dmax) −0.49 −1.07 0.87 0.33
Optic chiasm (Dmax) −0.30 −0.15 0.26 0.00
Average −0.52 0.29 0.59 0.72
Standard deviation 0.63 1.23 0.50 1.61
Head and neck 5 6 7 8
Cord (Dmax) −0.46 −0.11 0.06 0.24
Stem (Dmax) N/A −1.06 0.59 0.73
R parotid (Dmean) N/A −0.19 1.13 0.69
L parotid (Dmean) N/A −0.69 0.37 0.73
R SMG (Dmean) −0.91 −0.16 0.20 0.24
L SMG (Dmean) −0.28 −0.84 1.49 1.56
Esophagus (Dmean) −0.12 −0.21 0.36 0.59
Thyroid (Dmean) −0.12 −0.13 0.28 −0.21
Average −0.38 −0.42 0.56 0.57
Standard deviation 0.33 0.38 0.50 0.52
Chest 9 10 11 12
R lung (Dmean) −0.13 N/A −0.13 0.30
L lung (Dmean) 0.00 N/A 0.00 0.23
Cord (Dmax) −0.49 0.00 0.00 0.51
Esophagus (Dmean) 0.18 −0.21 −2.44 0.21
Heart (Dmean) 0.17 N/A −1.64 N/A
Average −0.05 −0.11 −0.84 0.31
Standard deviation 0.28 0.15 1.13 0.14
Abdomen 13 14 15 16
Liver (Dmean) −0.23 −0.26 0.49 0.36
Stomach (Dmean) −0.15 −0.10 0.32 0.19
Duodenum (Dmean) −0.32 −0.22 N/A N/A
Bowel (Dmean) −0.28 −0.31 0.46 0.24
Cord (Dmax) −0.44 −0.09 0.00 0.37
Average −0.28 −0.20 0.32 0.29
Standard deviation 0.11 0.10 0.22 0.09
Pelvis 17 18 19 20
R femur head (Dmean) −0.77 −0.39 0.36 0.28
L femur head (Dmean) −0.23 −0.19 0.20 0.21
Bowel (Dmean) −0.23 −0.35 0.05 0.27
Bladder (Dmean) −0.31 −0.26 0.21 0.16
Rectum (Dmean) −0.32 −0.10 N/A N/A
Average −0.37 −0.26 0.21 0.23
Standard deviation 0.23 0.12 0.13 0.06
R, right; L, left; SMG, submandibular gland; N/A, not available.
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no significant difference in conversion between the two 
groups. In the other three treatment sites, namely the brain, 
abdomen, and pelvis, the difference was within 3.0%. Al-
though the HI was slightly larger than the CI, the average of 
all treatment sites was 1.7%.
2) OARs dose
The difference in OARs between the original plans and 
the transferred plans was mostly within 1% across all treat-
ment sites, as shown in Table 3. The difference in the lens 
of the brain site was 4.34%, the largest among all treatment 
sites. However, other OARs showed a difference of less than 
1%. In the H&N and chest sites, the difference was more 
than 1% in the submandibular gland and in the esophagus, 
but for all other OARs, the difference was within 1%. Both 




The difference (%) in absolute dose between the treat-
ment plans converted from machine A to machine B was 
0.85% (Table 4). In the opposite case, the average value was 
0.62% (Table 5). The average difference (%) was 0.74%. The 
P-value was 0.46, indicating that the difference in conver-
sion of the absolute dose value between the two machines 
was not significant.
Table 4. Absolute dose differences between the treatment plan converted from the original machine A to the transferred machine B
Treatment site Patient
A machine  
measurement (nC)
B machine  
measurement (nC)
Difference (%)
Brain 1 3.51 3.51 −0.14
2 1.42 1.43 0.78
Head and neck 5 1.88 1.89 0.59
6 1.50 1.52 1.20
Chest 9 0.86 0.84 −2.33
10 2.76 2.74 −0.73
Abdomen 13 1.71 1.71 −0.18
14 1.76 1.79 1.71
Pelvis 17 2.18 2.19 0.28
18 1.69 1.70 0.59
Absolute mean value 0.85
Standard deviation 0.71
Table 5. Absolute dose differences between the treatment plan converted from the original machine B to the transferred machine A
Treatment site Patient
A machine  
measurement (nC)
B machine  
measurement (nC)
Difference (%)
Brain 3 2.34 2.35 0.43
4 3.37 3.39 0.59
Head and neck 7 1.54 1.54 −0.07
8 1.49 1.48 −0.67
Chest 11 1.37 1.37 0.51
12 3.57 3.57 −0.06
Abdomen 15 2.23 2.25 0.90
16 1.55 1.54 −0.65
Pelvis 19 2.27 2.30 1.32
20 3.17 3.14 −0.98
Absolute mean value 0.62
Standard deviation 0.39
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2) Film analysis
As shown in Table 6, the gamma passing rates using film 
measurement averaged at 99.64% at 3%/3 mm, with a pass-
ing rate of 99% or more for almost all sites. In addition, 2%/2 
mm also showed a high average gamma passing rate of 
97.08%.
Discussion
In this study, we compared original plans and transferred 
plans between two machines to verify the effectiveness 
of Accuray Precision’s Plan transfer function. Our results 
showed that the transferred plan was clinically valid in 
terms of DVH, absolute dose, and gamma passing rates 
analysis. In a previous study of the Samsung Medical Cen-
ter that attempted to confirm the effectiveness of the Plan 
transfer function, they compared the dosimetric difference 
on DVH of the treatment plan of H&N and prostate cases 
using a phantom between TOMO HDA and Radixact. Ac-
cording to the results, when the treatment plan was trans-
ferred, there was no significant difference in the target. 
However, when the treatment plan was transferred from 
TOMO HDA to Radixact, the dose increased in many nor-
mal organs [3]. Furthermore, several previous studies have 
investigated third-party TPS. Yuan et al. [4] confirmed the 
treatment plan of HT by its conversion to L-Linac using 
RayStation’s FB planning function. They concluded that 
overall dosimetric differences between FB plans and HT 
original plans were considered negligible and not clini-
cally significant, and FB plans were within ±10% for OAR 
avoidance. Furthermore, patient specific QA received >95% 
passing rate using the 3%/3 mm gamma analysis criteria [3]. 
In addition, Zhang et al. [5] investigated a RayStation’s FB 
planning function by generating three-dimensional (3D) 
and IMRT FB backup plans. They selected the HT as the ini-
tial treatment machine and L-Linac as a backup machine. 
They concluded that all the FB-IMRT plans were admissible 
for use. Although there were some statistical differences, 
these differences were unlikely to be clinically significant. 
However, they found that the FB-3D plans could fail to im-
plement the original HT plan and might require more time 
and effort to create acceptable plans [4]. 
Unlike in previous studies, the goal of this study was to 
verify Accuray Precision’s new feature of Plan transfer func-
tion between Radixact machines using its own conversion 
protocols and without using a third party TPS. In addition, 
twenty treatment plans were selected from various sites 
to evenly verify the entire body. With respect to PTV dose 
coverages, the average value for CI was 0.17% (with the ex-
ception of one case in the pelvis site), with most CI values 
showing a difference of less than 0.3%. This represents a 
good result and is similar to that of Zhang et al. [5]. In addi-
tion, the HI was slightly higher than the CI with an average 
difference of 1.72%. For the H&N and pelvic sites, which 
showed results significantly different from those obtained 
by Zhang et al. [5], our study found small differences of 2.8% 
and 0.9%, respectively. Our study also found little difference 
in OARs as compared with the results of Yuan et al. [4]. We 
found that differences in OAR doses were uniformly within 
±1% at all sites. However, in the lens, the average value was 
within 1%, although there was a maximum difference of 
4.34. The two figures below are dose distributions of the 
Table 6. Distribution of gamma passing rates
 Treatment site
Gamma % passing
Patient 3%/3 mm 2%/2 mm





















Standard deviation 0.70 3.45
Values are presented as percentage.
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case 4, who had the greatest dose difference in the right 
lens (Fig. 4, 5). Fig. 4 represents the image of the original 
treatment plan in machine B of case 4. Fig. 5 shows the 
treatment plan image of case 4 converted from machine B 
to machine A. This case is a whole brain radiation therapy 
with simultaneous integrated boost. Therefore, other in-
stitutions need more care if the target is near the lens and 
the dose of the lens is meant to be close to the threshold 
dose. Four cases were used for the brain in this study; 
hence, more cases will need to be studied in the future to 
determine whether there is a large difference in dose values 
when converting treatment plans to structures with smaller 
contours. A difference of greater than 1% was found in sev-
eral OARs in the H&N and chest sites.
In Radixact using the golden beam data, but there was a 
case where the difference between PTV dose coverage and 
OAR dose is large. According to Accuray, the transfer pro-
cess modifies the treatment delivery instructions to account 
for differences in field width, output, and MLC properties 
between two machines. As a cause of this difference, it can 
be assumed that the multileaf collimator (MLC) latency 
(delay time for MLC to fully open) influences the outcome 
of the treatment plan conversion. As a result of checking the 
machine of our institution, the offset of the leaves of machine 
A was −1.298 ms and the offset of machine B was −0.636 ms 
(Table 7). The offset of −1.298 ms from machine A means 
leaves are opening 1.298 ms less than programmed. The 
dose calculator will then use this offset value to adjust the 
commanded leaf open time (LOT). For example, if the 
requested open time is 100 ms, due to the correction, the 
requested time could be adjusted to 101.298 ms to compen-
sate for MLC latency uncertainty. Therefore, when we per-
form a Plan transfer to machine B with an offset of –0.636 
ms, the End-of-Planning/latency correction calculation 
would use this to reduce the open time from the original 
plan since the destination machine has less delay in actual 
LOT. Tomotherapy is a device that uses binary MLC, and it 
is one of the important components because it controls the 
dose delivered to the patient. However, after reducing the 
difference between the two machines by putting the up-
dated offset value of the MLC latency, we could not recheck 
whether the difference was reduced or not. Therefore, other 
institutions should check this factor and reconfirm whether 
it affects the converted treatment plan result. In addition, 
according to Accuray, the latency offset will be set to zero 
and that the latency offset is always updated every day by 
the system in the Radixact updated version. This will be a 
Table 7. Latency offset table obtained from machine A and machine B
Machine The offset (ms)
A machine −1.298
B machine −0.636
Fig. 4. The image of the original treatment plan of case 4 in 
machine B.
Fig. 5. The treatment plan image of case 4 converted from machine 
B to machine A.
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great improvement on how the system models the latency 
data and applies new values depending on the day’s MLC 
performance.
The difference in absolute dose measurements using 
ion chambers was 0.74% (absolute value) on average. The 
difference (%) in absolute dose values between treatment 
plans converted from machine A to machine B was 0.85% 
on average and had a maximum of –2.33%. When convert-
ing from machine B to machine A, the difference (%) was 
0.62% on average and had a maximum difference of 1.32%. 
The difference in absolute dose values between the two ma-
chines was insignificant, and the P-value of the difference 
in conversion between the two machines was 0.46, indicat-
ing that the absolute dose value was not significant when 
converting between the two machines.
As for the gamma passing rates analysis, the average was 
99.64% in the 3%/3 mm standard of general IMRT criteria, 
while the even more stringent 2%/2 mm criteria also had 
a value of 97.08% [16,17]. These results were superior to 
those obtained by previous studies, which found 98%±1% 
and >95% based on 3%/3 mm criteria [8,9]. We validated 
the effectiveness of the plan transfer features between 
two Radixacts sharing patient data in IDMS. This feature 
should also have the same effectiveness among other (non-
Radixact) types of HT machines connected through IDMS. 
By the result of this study, another user will need to extract 
some representative cases from each body site to verify the 
accuracy of the converted treatment plan. Perhaps it does 
not take too long to recover after machine breakdown; thus, 
most transferred plans are not used much. Therefore, it will 
have little impact in conventional scheduled treatment cas-
es. However, careful attention should be paid during short 
fractional treatments, such as stereotactic radiosurgery or 
stereotactic body radiotherapy.
Conclusions
Under normal circumstances, we usually proceed with 
the planned treatment plan. However, it is important to find 
a way to continue patient treatment in the event of con-
tingencies, such as machine breakdown. In this study, we 
worked to evaluate whether plans managed in IDMS are ac-
curately converted by using Accuray Precision’s Plan trans-
fer function. Our results confirmed that this feature is stable 
and reliable. However, there was a case where the difference 
between PTV dose coverage and OAR dose. This should be 
checked by each institution on how it affects the planning 
results by comparing the MLC latency table between the 
two machines. Using this function, a given treatment plan 
can be converted within five minutes and made available 
to continue treatment on another treatment machine. This 
will reduce stress among both clinicians and patients and 
improve treatment results.
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